Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial cell wall and plasma membrane are fundamental structures that provide physical protection and regulate the internal environment of bacteria (StatPearls, 2023). The cell wall is characterized by a complex peptidoglycan layer that provides mechanical strength and protects the cell from bursting due to high internal osmotic pressure (NCBI, 2022). Beneath the cell wall, the plasma membrane serves as a selective permeability barrier, regulating the transport of nutrients and waste while hosting critical enzymes for energy production (PubMed, 2021). These structures are the primary targets for several major classes of antibiotics, including beta-lactams, which inhibit the cross-linking of peptidoglycan, and glycopeptides like vancomycin (Merck Manual, 2023). Other agents, such as polymyxins and lipopeptides, target the membrane directly by disrupting lipid organization or creating pores that lead to rapid depolarization (StatPearls, 2023). Because these bacterial components are distinct from or entirely absent in human cells, they provide a basis for selective toxicity in treating a wide range of infectious diseases (PubMed, 2022). However, the effectiveness of these drugs is frequently compromised by bacterial resistance mechanisms, such as the enzymatic degradation of drugs or structural modifications to the target sites (WHO, 2023). Understanding the interplay between these envelope components is crucial for developing next-generation antimicrobials to combat multi-drug resistant pathogens (Nature Reviews Microbiology, 2021).
Drugs targeting these components act by inhibiting the synthesis of the peptidoglycan layer (e.g., beta-lactams and glycopeptides), binding to specific precursors like Lipid II (e.g., vancomycin), or directly disrupting the phospholipid bilayer or lipopolysaccharide integrity (e.g., daptomycin and polymyxins), leading to cell lysis and death (StatPearls, 2023; PubMed, 2022).
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial cell wall and plasma membrane components.